EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effect of Valve Type and Anesthesia Strategy for TAVR

Hans-Josef Feistritzer, Thomas Kurz, Reinhard Vonthein, Leonie Schröder, Georg Stachel, Ingo Eitel, Christoph Marquetand, Roza Saraei, Eva Kirchhof, Matthias Heringlake, Mohamed Abdel-Wahab, Steffen Desch und 2 weitere

Journal of the American College of Cardiology · 2025-01 · 85 (1) · 74-82

DOI: 10.1016/j.jacc.2024.09.007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2025-01. Verfasst von Hans-Josef Feistritzer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center Leipzig at University of Leipzig, Leipzig, Germany. Electronic address: hans-josef.feistritzer@medizin.uni-leipzig.de. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Heart Valve Prosthesis. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Deutsche Stiftung für Herzforschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In the randomized SOLVE-TAVI (compariSon of secOnd-generation seLf-expandable vs. balloon-expandable Valves and gEneral vs. local anesthesia in Transcatheter Aortic Valve Implantation) trial comparing newer-generation self-expanding valves (SEV) and balloon-expandable valves (BEV), as well as conscious sedation (CS) and general anesthesia (GA), clinical outcomes were similar both for valve and anesthesia comparison at 30 days and 1 year. Prosthesis durability may affect clinical outcomes during long-term follow-up. Moreover, the impact of the anesthesia strategy on long-term clinical outcomes is unknown so far. OBJECTIVES: The authors sought to compare clinical outcomes during 5-year follow-up in the randomized SOLVE-TAVI trial. METHODS: In the randomized, multicenter, 2 × 2 factorial, open-label SOLVE-TAVI trial, 447 intermediate- to high-risk patients with severe, symptomatic aortic stenosis were randomly assigned to transfemoral transcatheter aortic valve replacement (TAVR) using either SEV (Evolut R, Medtronic) or BEV (SAPIEN 3, Edwards Lifesciences) and also to CS vs GA. Patients were followed-up for 5 years. RESULTS: During 5 years of follow-up, the combined predefined endpoint of all-cause mortality, stroke, moderate or severe paravalvular leakage, and permanent pacemaker implantation was similar in the SEV and BEV groups (67.7% vs 63.4%; HR: 0.89; 95% CI: 0.70-1.13; P = 0.34). Stroke rates at 5 years were lower in the SEV group (2.2% vs 9.6%; HR: 4.84; 95% CI: 1.65-14.18; P = 0.002). Regarding the anesthesia comparison, the primary endpoint of all-cause mortality, stroke, myocardial infarction, and acute kidney injury occurred in 51.4% in the CS group and 61.3% in the GA group (HR: 0.80; 95% CI: 0.62-1.04; P = 0.09). All-cause mortality at 5 years was lower for CS (41.5% vs 54.3%; HR: 0.70; 95% CI: 0.53-0.94; P = 0.02). CONCLUSIONS: Transfemoral TAVR using either SEV and BEV as well as CS and GA showed similar clinical outcomes at 5 years using a combined clinical endpoint.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisHeart Valve ProsthesisHumansFemaleMaleAged, 80 and overFollow-Up StudiesAgedAnesthesia, GeneralTreatment OutcomeProsthesis DesignAortic ValveTime FactorsPostoperative Complications

Stichwörter der Autor:innen

anesthesiaaortic stenosisprognosistranscatheter aortic valve implantationtranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Heart Center Leipzig at University of Leipzig, Leipzig, Germany. Electronic address: hans-josef.feistritzer@medizin.uni-leipzig.de.
  • University Heart Center Lübeck, Lübeck, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg-Kiel-Lübeck, Lübeck, Germany.
  • Institute of Medical Biometry and Statistics, Lübeck, Germany.
  • Heart Center Leipzig at University of Leipzig, Leipzig, Germany; Clinic and Policlinic for Cardiology, Leipzig University Clinic, Leipzig, Germany.
  • Helios Health Institute, Leipzig, Germany.
  • Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Förderung

  • Deutsche Stiftung für Herzforschung

Zitieren

APA

Feistritzer, H. J., Kurz, T., Vonthein, R., Schröder, L., Stachel, G., Eitel, I., Marquetand, C., Saraei, R., Kirchhof, E., Heringlake, M., Abdel-Wahab, M., Desch, S., Thiele, H., & SOLVE-TAVI Investigators (2025). Effect of Valve Type and Anesthesia Strategy for TAVR. Journal of the American College of Cardiology, 85(1), 74-82. https://doi.org/10.1016/j.jacc.2024.09.007

Vancouver

Feistritzer HJ, Kurz T, Vonthein R, Schröder L, Stachel G, Eitel I, et al. Effect of Valve Type and Anesthesia Strategy for TAVR. Journal of the American College of Cardiology. 2025;85(1):74-82. doi:10.1016/j.jacc.2024.09.007

BibTeX
@article{Feistritzer2025,
  author = {Feistritzer, Hans-Josef and Kurz, Thomas and Vonthein, Reinhard and Schröder, Leonie and Stachel, Georg and Eitel, Ingo and Marquetand, Christoph and Saraei, Roza and Kirchhof, Eva and Heringlake, Matthias and Abdel-Wahab, Mohamed and Desch, Steffen and Thiele, Holger and SOLVE-TAVI Investigators, SOLVE-TAVI Investigators},
  title = {Effect of Valve Type and Anesthesia Strategy for TAVR},
  journal = {Journal of the American College of Cardiology},
  year = {2025},
  volume = {85},
  number = {1},
  pages = {74--82},
  doi = {10.1016/j.jacc.2024.09.007}
}
Kostenlos starten →